1. Yumin Cui, Zhihua Huang, Hanyang Chen, Xinfeng Zhang, Bo Qi, Heng Liu and Xiaoqiang Yan (2016). A-337, a potent bispecific antibody targeting EpCAM×CD3, as a potential immunotherapeutic agent for human solid tumors.
https://cancerres.aacrjournals.org/content/76/14_Supplement/2359
2. Yumin Cui, PhD, Zhihua Huang, MSc, Xinfeng Zhang, PhD, Wuzhong Shen, MSc, Hanyang Chen, PhD, Zaiqing Wen, PhD, Bo Qi, MSc, Lan Luo, MSc, Ying Tan, Yun Wu, PhD, Ada Kung, PhD, Xiaoqiang Yan, PhD (2018). CD3-Activating Bi-Specific Antibody Targeting CD19 on B Cells in Mono- and Bi-Valent Format. (2018)
https://ashpublications.org/blood/article/132/Supplement%201/4169/275791/CD3-Activating-Bi-Specific-Antibody-Targeting-CD19
3. Sisi Wang, Lijun Peng, Wenqian Xu, Yuebo Zhou, Ziyan Zhu, Yushan Kong, Stewart Leung, Jin Wang, Xiaoqiang Yan, Jian-Qing Mi (2021). Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 tri-specific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia. Front. Med.
https://doi.org/10.1007/s11684-021-0835-8.
4. Aran F. Labrijn, Maarten L. Janmaat, Janice M. Reichert & Paul W. H. I. Parren (2019). Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery volume 18, p585–608 (2019).
https://www.nature.com/articles/s41573-019-0028-1
5. Cappell, K.M., Kochenderfer, J.N. Long-term outcomes following CAR T cell therapy: what we know so far.Nat Rev Clin Oncol 20, 359–371 (2023).
https://doi.org/10.1038/s41571-023-00754-1
